Novartis second offer for Genoptix

Novartis said yesterday it would begin a second offer period for shares in US cancer diagnostics company Genoptix after securing acceptances for 80 per cent in the initial offer. The holders of shares tendered in the second period, which closes on 4 March, will be paid $25 per share, the same amount offered in the initial offer period, the Swiss drugmaker said.